$BMTLE Green Baron Alert -- Good cover las
Post# of 144499
$BMTLE Green Baron Alert -- Good cover last year |
Thursday, January 13, 2011 – Before Market Open New Green Baron “Stock Alert” BioMedical Technology Solutions
(BB: BMTL - $.29 per share) Common Shares Outstanding: 32,082,398 Market Cap: $9.3 Million Three-Year High: $2.00 52-Week High: $.50 52-Week Low: .10 Average Price: $.2701 (50-day) $.2747 (200-day) Average Volume: 5,796 (50-day) 13,911 (200-day) BioMedical Technology’s Patented Demolizer® II Offers a Cost-effective, Safe, Simple and Secure Solution to Biomedical Waste Disposal Major News Issued Tuesday, January 11 After Close: BioMedical Technology Solutions Receives Signed LOI Valued in Excess of $2 Million from New International Distributor Demolizer® II is World’s only Portable and Patented Machine that Processes Both Sharps and Typical “Red Bag” Waste Onsite so it can be Disposed of as Common Trash The Green Baron Believes Revenues will Skyrocket in 2011; Company has Superior Product in Multi-Billion Dollar Industry, and We Identify BMTL as a Takeover Target The road to profitability for companies in the medical industry is a challenge. There are almost always regulatory hurdles, stiff competition, barriers to entry, and aggressive sales tactics from large industry players. Even if a company has a superior product, it is not always an automatic ticket to success. Today’s new stock selection is a Company we believe has the best product in a multi-billion dollar industry. It is managed and advised by industry veterans. The product is patent protected and is considered revolutionary intellectual property. We firmly believe it is the right product at the right time, but Company has been slow to deliver – UNTIL NOW! The Green Baron Report has selected BioMedical Technology Solutions Holdings, Inc. (OTCBB: BMTL) as our newest Green Baron “Stock Alert”, and we strongly suggest members accumulate the stock as close to our profile price as possible. Results compiled from the most recent trade prior to dissemination of this report to the subsequent high will be closely monitored at www.thegreenbaron.com and through email updates to members. We have very aggressive price projections for BMTL and believe the stock has huge upside potential based on several positive fundamental factors. TRADER’S NOTES: BMTL is a fully registered and reporting company traded on the OTCBB and OTCQB. BMTL hit highs of $2.00 in 2008, $1.15 in 2009 and .50 in 2010. BMTL now trades near at all-time low even though fundamentals seem to be gaining strength. The stock is represented by a respectable number of market makers, but low volume since June of last year has kept the stock in a tight range. We believe new contracts can breathe life into BMTL, and the stock has realistic potential to return to levels seen just a few years ago. BioMedical Technology Solutions Holdings, Inc. sells the Demolizer® II through its wholly owned subsidiary BioMedical Technology Solutions, Inc. BMTS' patented Demolizer® Technology converts infectious biomedical waste into non-infectious material. BMTS' products provide biomedical waste treatment solutions for the over 1,000,000 low to medium volume medical waste generators in the US and a global market five times larger than the US. In the United States alone, biomedical waste is on the rise. In 2008, over five pounds of medical waste was generated for each person in the United States. This equates to 1.5 billion pounds that must be accounted for and properly disposed according to government regulations. Twenty years ago, the industry was only valued at approximately $750 million. Growing at approximately a 25% rate, the industry surged through $1 billion in 1995 and is conservatively estimated that it will reach $3.2 billion annually by the year 2015. The Green Baron Report, in conjunction with a recent report from All Penny Stocks dated January 11, 2011, has identified the following reasons for accumulation of BMTL now:
About BioMedical Technology Solutions Holdings, Inc. BioMedical Technology Solutions Holdings, Inc., located in Englewood, Colorado, sells the Demolizer® II through its wholly owned subsidiary BioMedical Technology Solutions, Inc. BMTS' patented Demolizer® Technology converts infectious biomedical waste into non-infectious material. BMTS' products provide biomedical waste treatment solutions for the over 1,000,000 low to medium volume medical waste generators in the US and a global market five times larger than the US. About the Demolizer® II The Demolizer ® II is the GREEN alternative to biomedical waste disposal. The device is the only patented, portable, and self-contained system able to process both sharps and typical red bag biomedical waste onsite. The processed waste is rendered sterile and discarded as common trash eliminating up to 100% of the cost associated with its disposal. The Demolizer® II meets or exceeds all EPA and CDC guidelines and is approved or meets treatment requirements in 48 states after review by 80 governmental agencies. The device uses no chemicals or liquids, plugs into a normal outlet through a surge protector, and automatically records and prints state required documentation. The Demolizer® II provides a safer, more environmentally GREEN method for biomedical waste disposal. Market Opportunities The Demolizer® II offers a cost-effective, safe, simple and secure solution to biomedical waste disposal. 1. Clinical Solutions In the United States alone, there are over half a million private, outpatient medical and dental offices. Every day, routine patient treatment at these offices generates potentially infectious biomedical waste. Without proper and efficient processing, accumulation, storage and carting of these wastes can result in unnecessary exposure risk to both patients and staff. Generator's liability for their biomedical waste does not end with hauler pick-up. Under the Resource Conservation and Recovery Act (Environmental Protection Agency, 42 U.S.C. s/s 6901 et seq., 1976) generators are liable for their biomedical waste from point of generation through treatment and proper disposal – cradle-to-grave. 2. Skilled Nursing care In the past fifty years, the U.S. elderly population has grown at twice the rate of the general population. It is estimated that by 2030, 70 million Americans will be 65 or older, comprising twenty percent of the population. · 42% of people 65 years and older report a long lasting medical condition · 7% of people 65 years or older need assistance with daily living activities · 56% of women and 38% of men will be living in a nursing home, or other assisted living facility, by the time they reach their 85th birthday. These population statistics clearly indicate the growing need for long term healthcare. In fact, the majority of physicians in training today will spend 50% of their future practice time treating patients over the age of 65. Currently there are more than 40,000 skilled nursing care facilities in the United States, including nursing homes, assisted living facilities and hospices. Each patient's treatment in a skilled nursing care facility produces approximately 8 ounces of biomedical waste per day. As the need for skilled nursing care increases, there is a more pressing need for safe and efficient processing of these potentially infectious wastes. 3. Home Healthcare Many conditions exist today that require a need for home healthcare and that need is expected to grow 20% annually. As an industry, home care has grown at the rate of 20% per year for more than 10 years. 88% of the physicians surveyed reported at least one referral to a home health agency within the past year. In the U.S. alone, an estimated 8 million people administer over 3 billion injections at home annually. These numbers are expected to grow by 165% over the next ten years due to changes in demographics. Because diabetics and other self-treatments can also be administered while at public venues, disposal of this medical waste poses significant challenges at the local level. The State of California is leading the way, and in 2008 will require that all medical waste, including sharps waste generated in self-care, be treated prior to disposal, due to the risks this waste poses to public health and the environment. Massachusetts has new laws requiring home generated sharps waste to be treated prior to disposal. Many other states have guidelines, and will soon require safe disposal for home health generated biomedical waste. 4. Public Venues There are virtually hundreds of thousands of public settings where biomedical waste is generated in the form of both sharps (e.g. syringes, razors) and red bag biomedical waste: · Public Health Clinics · Urgent Care Clinics · School Health Clinics · First Aid Stations · Ambulances · Air Evacuation Vehicles · Stadiums · Airports · Cruise Lines, Trains, Buses, Airplanes · Pharmacies Additionally, restrooms located in public settings often serve as a makeshift facility for self-treatment, producing potentially infectious waste that should be properly processed for safe disposal. 5. Veterinary Medicine There are approximately 55,000 veterinarians in private practice in the United States alone. An additional 8,000 treat animals as part of their role in academic and government positions. In veterinary medicine, potentially infectious wastes are produced as a result of routine examination, immunizations and treatment. In light of growing concern regarding the danger of zoonotic disease, proper handling and disposal of such wastes are necessary for the safety of both veterinary staff and waste management personnel. The Demolizer® technology is the ideal on-site veterinary biomedical waste disposal solution for: · Veterinary Clinics, Hospitals and Emergent Care Centers · Schools of Veterinary Medicine · Mobile Veterinary Practices · Veterinary/Animal Research Centers · Animal Rescue Organizations · Mobile Veterinary Medical Assistance Teams (VMATs) 6. Government Applications There are approximately 1.5 million active duty military personnel in the United States armed forces and another 1.2 million on the reserve rolls. Healthcare in support of military missions is frequently dispensed by means of mobile services (air evacuation, naval ships, ambulance) and field care (temporary treatment facilities). The U.S. Air Force employed Demolizer® technology in theatre , to effectively process waste on site. Future plans for BMTS BMTS is committed to working with the armed forces medical branches, as well as the Department of Homeland Security, to offer the innovative Demolizer® technology as a solution to their unique biomedical waste disposal needs. The 4 S’s - Savings, Safety, Simplicity and Security One - Save Money BMTS has often heard practitioners say that they work longer hours, yet make less money. One way to combat making less is by saving more. Customers have saved tens of thousands using the Demolizer® II and eliminating their biomedical waste hauling costs. Because each facility is different, savings vary. BMTS is happy to provide a FREE, no-obligation cost analysis to show any potential customer how much their facility can save using the Demolizer® II. Two - Create Safer Facilities Many customers used to store and handle their biomedical waste multiple times: bagging and tagging and preparing for pick-up. The Demolizer® II eliminates their need to store waste because they can now quickly process it, as needed, on-site. The system is safe for any setting and runs quietly at a comfortable, ambient external temperature. The Demolizer® patented filtration system prevents unwanted odors. Three - Simple to Operate Sharps and red bag waste are deposited into their respective collectors. When full, collectors are placed in the Demolizer® II and processed with the simple push of a button. After the process is complete, waste is rendered sterile and can be tossed into the common trash. The system plugs into a standard electrical outlet and requires no chemical solutions or special set-up. About the size of a desktop printer, the Demolizer II® fits easily on a counter or cart. Four - Secure Your Confidence in a Proven Technology The Demolizer® II is a smart system, constantly self-monitoring and controlling all regulatory system requirements as waste is processed. Once the process is completed, the system automatically generates labels for immediate documentation, then stores process data, making state required documentation effortless and the generator's cradle-to-grave liability virtually eliminated. Incineration is the leading cause of dioxins and other harmful toxins entering the environment. Unlike incineration, the dry heat technology used by the Demolizer® II does not emit harmful fumes into our atmosphere. Because processed waste is sterile, and sharps are rendered unrecognizable, dangers from toxic exposure or needle sticks are eliminated. The Demolizer® II system is designed to meet or exceed the standards or guidelines for biomedical waste treatment by the EPA, CDC and state regulatory agencies. Laws and regulations for medical waste treatment and disposal are managed at the state or local level. The Demolizer® technology has been reviewed by over 80 governmental agencies and is either formally approved or meets regulatory requirements for treatment in 48 U.S. states . Recent Key Press Releases Tuesday, January 11, 2011 - BioMedical Technology Solutions Receives Signed Letter of Intent Valued in Excess of $2 Million From New International Distributor - ENGLEWOOD, CO - (Marketwire) - BioMedical Technology Solutions Holdings, Inc. ("BMTS") (OTC.BB: BMTL) is pleased to announce the signing of a Letter of Intent ("LOI") with a new international distributor, JATA Technology Solutions Ltd., with a targeted performance goal for the sale of 250 to 500 Demolizer® II units throughout the calendar year 2011. At standard pricing, the value of the contract will represent revenues in excess of $2 million for BMTS; more than doubling orders in 2010. The distributor intends for distribution to be focused initially on the largest country in Africa, where insufficient biomedical waste management has reached epic proportions and demand is strong for a solution. The LOI provides incentives for the distribution firm to increase purchases throughout the year while maintaining guidelines for minimum purchases at specific intervals. Additionally, the agreement sets forth guidelines for 2012 and future years with minimum orders of 500 units as well, securing future revenues for BMTS. The country of Africa is in the midst of a concerted effort to curtail improper disposal of biomedical waste. Incineration is one of the few options for sharps destruction in Africa with most incinerators poorly maintained and, in many cases, not operational. As a result, biomedical waste is often burned openly causing hazardous conditions or simply dumped leaving people vulnerable to the dangers of untreated sharps waste that can be scavenged, repackaged and reused or spread disease from needlestick injuries. What has been called a "health catastrophe," the poor practices for sharps waste management leads to the senseless spread of blood-borne diseases including HIV. The Demolizer® II offers an ideal solution to this ever-growing problem. Sharps are treated and destroyed at the clinic using a safe, non-incineration technology. The treated waste is safe for final disposal or recycling. Through adoption of this important technology, clinics can take responsibility for proper waste treatment and prevent the unnecessary spread of disease. "We are extremely excited about this Letter of Intent as it is the international breakthrough that we have been working towards for our company and shareholders," stated Don Cox, CEO of BioMedical Technology Solutions. "Our team has been working diligently to secure contracts for 2011 and we believe that this is just the start of a significant market penetration as awareness about the benefits of the Demolizer® II continues to spread both domestically and internationally. With the execution of this LOI, not including new and recurring orders that we are anticipating, BMTS will have the best revenue-generating year in its history and will help us achieve a fair market valuation." Tom Von Bank, National Sales Director of BMTS, commented, "Proper biomedical waste disposal is a growing concern globally and a focus of African nations to institute change for the safety of their people and environment. This order is large, but still only represents a small portion of our new client's distribution base. The potential is vast in this multi-billion dollar industry and we will continue to work closely with our new partner to expand distribution throughout Africa and other countries." Wednesday, December 15, 2010 - BMTL Expands Reach to the Physician Market Through a New Distribution Agreement With GroupSource - ENGLEWOOD, CO--(Marketwire) - BioMedical Technology Solutions Holdings, Inc. ("BMTS") (OTC.BB: BMTL) is pleased to announce the signing of a distribution agreement with GroupSource for the sale of its Demolizer® II System. GroupSource is a Lenexa, Kansas, based corporation founded in 1996. As a group purchasing organization focused on the physician market, GroupSource uses collective leverage to help its members reduce hard dollar costs for supplies and services with over 100 contracts from nearly all of the medical-related supply/services contracts required by a physician practice to general office supplies, credit card processing and telecommunications. GroupSource has been endorsed by many organizations who serve as advocates for the physician community including the North Carolina Medical Society, Louisiana State Medical Association, South Carolina Medical Society and the Colorado Medical Society, and others representing over 130,000 physicians. Ross Conner, CEO for GroupSource, stated, "We are excited to announce our newest contract with BMTS. Using the latest innovations in waste management, the Demolizer® II offers our members the opportunity to better manage and significantly reduce the costs associated with medical waste. We are especially excited about the return on investment this solution and our contracted rates offer our members." "With a 93% retention rate, GroupSource has one of the highest customer loyalty rankings in the industry, which adds significantly to our strategic marketing efforts by generating greater awareness of the Demolizer® II system nationally," said Tom Von Bank, BMTS' National Director of Sales. Further stating, "GroupSource also has a long-standing and very strong relationship with Henry Schein, one of our largest national distributors. In fact, Henry Schein is the leading supplier to the GroupSource network. This is important since we realize a three-fold better closing ratio when working through strong distribution partners compared to direct sales. We expect the synergistic relationship between BMTS, GroupSource and Henry Schein to greatly enhance our reach into the physician marketplace." Tuesday, November 16, 2010 - BioMedical Technology Solutions Strengthens International Position With New Russian Patent for Demolizer(R) II Technologies - ENGLEWOOD, CO--(Marketwire) - BioMedical Technology Solutions Holdings, Inc. ("BMTS," "the Company") (OTC.BB: BMTL) is pleased to announced that it has been informed by the Eurasian Patent Office that a new Russian patent titled "Heat Processing Systems, Apparatuses, and Methods for Collection and Disposal of Infectious and Medical Waste" has been awarded to the Company. The new patent covers major novel improvements, including system efficiencies, to the Demolizer® II technology since the original patent was issued in the United States. The patent was filed in 2007 and will be effective through the year 2027. With a population of 142 million people, Russia, much like many other countries, is in the midst of finding an environmental-friendly solution to mounting biomedical waste production. Conservative numbers show that approximately 500 million pounds of medical waste is generated in Russia each year with several challenges existing for cost-effective and safe disposal, including limited options in on-site treatment and exorbitant costs for removal by service companies. The Demolizer® II offers a cost-effective, green solution to these issues. BioMedical Solutions CEO, Don Cox, commented, "This is another major accomplishment for our company as it protects our proprietary technologies in Russia. International Medical Waste Services has been active in pursuing clients in South American and now is also exploring the Russian market as we continue to expand awareness of the Demolizer® II in international markets." Mr. Cox continued, "We are gaining momentum, as in the third quarter sales and efficiency increased dramatically, and we are hoping to continue this growth and performance throughout the fourth quarter for our company and shareholders." Tuesday, October 5, 2010 - BioMedical Technology Solutions, Inc. and Distribution Partner, Henry Schein, Continue Nationwide Roll-Out of Demolizer(R) II in US HealthWorks Locations - BioMedical Technology Solutions Holdings, Inc. (OTC.BB: BMTL), through its wholly-owned subsidiary, BioMedical Technology Solutions ("BMTS") is pleased to announce that the next round of Demolizer® II units have been received by US HealthWorks for placement throughout its nationwide health centers. As part of a continuing initiative to provide its network with "green" alternatives that can reduce costs through cutting-edge technologies for biomedical waste disposal, US HealthWorks is continually expanding its placement of Demolizer® II units throughout the United States. US HealthWorks' research has proven that their biomedical waste disposal costs have been reduced by 70% at facilities using the Demolizer® II System. Tom Von Bank, National Director of Sales for BMTS, commented, "We're excited with the expansion of the Demolizer® II throughout US HealthWorks. Through our partnership with Henry Schein and the assistance of their Senior Sales Rep, Kip Kula, the national roll-out is going extremely well." Mr. Von Bank continued, "We are presently in the final planning stages with US HealthWorks as to the details of the next placement schedule, which will then translate to over 30% of the US HealthWorks' facilities utilizing the Demolizer® II." BMTS CEO, Don Cox, stated, "The pace of our distribution is growing exponentially. The rate of growth is a product of the superior performance and cost-saving capacities of the Demolizer® II System as well as a strong 'green' initiative coupled with the overwhelming level of acceptance from staff and management that use the unit daily." Mr. Cox further said, "We are currently in both domestic and international negotiations and look forward to continued accelerated growth." Green Baron Conclusion BioMedical Technology Solutions has developed a product that ought to be the leader in its industry. It is a challenge to bring a superior product into a market dominated heavily by a few large players. Regardless of this challenge, the world market is so large and there are so many opportunities, we believe BioMedical Technology’s Demolizer® II will start to penetrate the industry. In the coming weeks and months, The Green Baron Report predicts that BioMedical Technology will begin to exceed its projections. The Company has frustrated its shareholder base through slow development, but this can all change if several significant contract orders are signed. A new LOI to deliver up to 500 units this year was just signed and announced a few days ago. A few more orders of this magnitude could send the stock screaming higher. BMTL is at a historic low, and appears to be coming off a long-term base. We urge members and investors to monitor this stock closely, and seriously consider accumulation at these levels. Contact: BioMedical Technology Solutions, Inc. |